TI
FATE icon

Telemetry Investments’s Fate Therapeutics FATE Stock Holding History

Telemetry Investments’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-40,000
Closed -$454K – 132
2018
Q2 		$454K Sell
40,000
-30,200
-43% -$333K 0.17% 64
2018
Q1 		$685K Sell
70,200
-20,923
-23% -$200K 0.26% 66
2017
Q4 		$557K Sell
91,123
-68,877
-43% -$307K 0.21% 71
2017
Q3 		$634K Sell
160,000
-65,700
-29% -$223K 0.23% 62
2017
Q2 		$731K Buy
225,700
+75,700
+50% +$290K 0.34% 57
2017
Q1 		$682K Buy
150,000
+26,500
+21% +$96.9K 0.31% 51
2016
Q4 		$310K Buy
123,500
+16,950
+16% +$45.4K 0.18% 69
2016
Q3 		$332K Buy
106,550
+21,550
+25% +$52.3K 0.21% 61
2016
Q2 		$144K Sell
85,000
-11,500
-12% -$20.9K 0.08% 103
2016
Q1 		$174K Buy
96,500
+26,507
+38% +$54.6K 0.05% 90
2015
Q4 		$236K Buy
+69,993
New +$294K 0.08% 104

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Telemetry Investments's FATE Position: Q3 2018 in Review

Telemetry Investments sold out of Fate Therapeutics (FATE) in Q3 2018, closing a stake of 40,000 shares — an estimated $454K sold.

Telemetry Investments first reported a position in FATE in Q4 2015 and held it in 11 quarters. The position peaked at $731K in Q2 2017. 116 funds tracked by Wall St. Rank hold FATE as of Q3 2018.

  • Telemetry Investments reported no remaining Fate Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Telemetry Investments sold 40,000 Fate Therapeutics shares in Q3 2018, an estimated $454K.
  • Telemetry Investments first reported a position in Fate Therapeutics in Q4 2015 and held it in 11 quarters.
  • Telemetry Investments's Fate Therapeutics position peaked at $731K in Q2 2017.
  • 116 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2018.

Based on Telemetry Investments's 13F filing for Q3 2018, filed 14 Nov 2018.